echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Science News > Novart confirms The long-term efficacy and safety of Emwave

    Novart confirms The long-term efficacy and safety of Emwave

    • Last Update: 2021-02-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    new data from Novarma confirm the long-term efficacy and safety of erenumab for most people with seizure migraines.
    The pharmaceutical giant announced the results of a five-year open-label treatment that examined the drug's continued efficacy and long-term safety and found that 77 percent of patients had reduced their monthly migraine days (MMD) by at least 50 percent after 4.5 years, 33 percent of patients who continued treatment had achieved a 100 percent reduction, and 56 percent had achieved a 75 percent reduction in MMD.
    These additional long-term data complement Amway's position as the most prescribed anti-CGRP drug, with more than 250,000 patients worldwide receiving prescriptions since its launch.
    According to Estelle West-Brolan, head of global neuroscience medicine, the company said it was "delighted to see that during OLTP, Amway not only reduced the number of migraine days per month, but also the number of days required for acute migraine-specific medications," adding that "these 4.5 years of data further add to the established benefits of Amway for migraine sufferers." Novaral is committed to reimagining migraine treatment to provide patients with effective preventive treatment options to recover from this extremely weak disease. As
    , the Scottish Medicines Union (SMC) accepted the drug for patients with chronic migraines, with at least three other preventive drugs not used successfully.Earlier this year, Ammerway also caused a stir when Amway and Novarma sued each other in federal court over Novarma's decision to sign a production contract with Alder Biopharmaceuticals, which is developing Amway's potential rival. (cyy123.com)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.